A detailed history of Royal Bank Of Canada transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 9,259 shares of COGT stock, worth $72,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,259
Previous 9,220 0.42%
Holding current value
$72,590
Previous $77,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.24 - $11.48 $321 - $447
39 Added 0.42%
9,259 $99,000
Q2 2024

Aug 14, 2024

BUY
$6.01 - $9.04 $44,227 - $66,525
7,359 Added 395.43%
9,220 $77,000
Q1 2024

Nov 05, 2024

SELL
$4.38 - $9.02 $32,232 - $66,378
-7,359 Reduced 79.82%
1,861 $12,000
Q1 2024

May 15, 2024

SELL
$4.38 - $9.02 $105,536 - $217,336
-24,095 Reduced 92.83%
1,861 $12,000
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $57,639 - $143,105
14,197 Added 120.73%
25,956 $152,000
Q3 2023

Nov 14, 2023

BUY
$9.69 - $13.34 $59,390 - $81,760
6,129 Added 108.86%
11,759 $114,000
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.24 $19,965 - $26,837
2,027 Added 56.26%
5,630 $66,000
Q1 2023

May 15, 2023

SELL
$10.04 - $15.5 $36,565 - $56,451
-3,642 Reduced 50.27%
3,603 $38,000
Q4 2022

Feb 14, 2023

BUY
$10.65 - $14.84 $65,838 - $91,740
6,182 Added 581.56%
7,245 $83,000
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $7,624 - $13,795
812 Added 323.51%
1,063 $16,000
Q2 2022

Aug 15, 2022

SELL
$3.92 - $9.73 $7,965 - $19,771
-2,032 Reduced 89.01%
251 $2,000
Q1 2022

May 16, 2022

SELL
$5.31 - $8.7 $25,944 - $42,508
-4,886 Reduced 68.15%
2,283 $17,000
Q4 2021

Feb 14, 2022

BUY
$7.51 - $10.81 $25,098 - $36,127
3,342 Added 87.33%
7,169 $61,000
Q3 2021

Nov 15, 2021

BUY
$5.99 - $9.14 $7,685 - $11,726
1,283 Added 50.43%
3,827 $32,000
Q2 2021

Aug 16, 2021

BUY
$7.82 - $9.3 $19,894 - $23,659
2,544 New
2,544 $21,000

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $516M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.